StockNews.AI
PYPD
StockNews.AI
202 days

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

1. PolyPid will report Q4 and full-year results on February 12, 2025. 2. Conference call at 8:30 AM ET will discuss financials and operations. 3. Lead product D-PLEX100 is in Phase 3 trials for surgical infections. 4. OncoPLEX is in preclinical testing for glioblastoma treatment. 5. Company aims to enhance surgical outcomes with innovative drug delivery.

4m saved
Insight
Article

FAQ

Why Bullish?

Anticipation of strong results could positively influence investor sentiment, similar to past earnings surprises.

How important is it?

Earnings reports can significantly impact stock prices, especially for biotech firms.

Why Short Term?

Upcoming earnings report could lead to immediate effects on stock price.

Related Companies

PYPD
January 29, 2025 07:00 ET  | Source: PolyPid Ltd. PETACH TIKVA, Israel, Jan. 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full-year 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 12, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast. Conference Call Dial-In & Webcast Information:  Date: Wednesday, February 12, 2025 Time:8:30 AM Eastern Time Conference  Call:https://register.vevent.com/register/BI4e72dffa5a7b4167a28a33a6b3097df3 Webcasthttps://edge.media-server.com/mmc/p/7uzqoye3    About PolyPidPolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma. For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites. Contacts:  PolyPid Ltd. Ori WarshavskyCOO – US908-858-5995IR@Polypid.com Investors:Brian RitchieLifeSci Advisors212-915-2578Britchie@lifesciadvisors.com

Related News